カテーテル関連血流感染症の世界市場

カテーテル関連血流感染症の世界市場は2030年までに19億米ドルに達する見込み

2024年に15億米ドルと推定されるカテーテル関連血流感染症の世界市場は、2030年には19億米ドルに達し、分析期間2024-2030年のCAGRは4.0%で成長すると予測されます。本レポートで分析したセグメントの1つである抗微生物剤は、CAGR 4.8%を記録し、分析期間終了までに12億米ドルに達すると予測されます。抗生物質ロック療法分野の成長率は、分析期間中CAGR 2.7%と推定されます。

米国市場は3億9,890万米ドルと推定、中国はCAGR7.5％で成長予測

米国のカテーテル関連血流感染症市場は、2024年に3億9,890万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに3億8,000万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と3.1%と予測されています。欧州では、ドイツがCAGR 2.3%で成長すると予測されています。

世界のカテーテル関連血流感染症（CRBSI）市場- 主要動向と促進要因まとめ

なぜカテーテル関連血流感染症はクリティカルケアと病院感染管理における根強い課題なのか？

カテーテル関連血流感染症（CRBSI）は、臨床現場、特に集中治療室、腫瘍病棟、長期療養施設において、罹患率、死亡率、ヘルスケアコスト増加の重大な原因となっています。これらの感染症は血管内カテーテルに病原菌が定着することで発生し、全身性の血流感染症を引き起こして治療成績を悪化させ、入院期間を延長させる。中心静脈カテーテル（CVC）は薬物投与、非経口栄養、および血行動態モニタリングに広く使用されているため、CRBSIは深刻な院内感染リスクであり、病院の感染制御プロトコールに負担をかけ続けています。

認知度の向上にもかかわらず、無菌的挿入手技の不徹底、カテーテル留置時間の長期化、および抗菌薬耐性のために、CRBSIの世界の負担は依然として続いています。予防可能な感染を最小限に抑える必要性は、ヘルスケアシステムが品質指標、患者の安全性、コスト抑制を優先するにつれて強まっており、CRBSIをターゲットとした高度な予防ツール、診断、バンドルケアソリューションに対する需要が持続的に高まっています。

カテーテル材料、抗菌コーティング、感染サーベイランスの革新はCRBSI予防をどのように改善しているか？

医療機器メーカーは、微生物の付着やバイオフィルムの形成を阻害する抗菌・防腐コーティング（銀スルファジアジン、クロルヘキシジン、ミノサイクリン・リファンピンなど）の使用を通じてカテーテル技術を進歩させています。このようなコーティングを施したカテーテルは、バスキュラーアクセスの機能を損なうことなく感染率を低下させるため、リスクの高い環境で採用されるようになってきています。カテーテル挿入キット、固定器具、透明ドレッシング材の改良により、感染バリア保護はさらに強化されています。

電子カルテ（EHR）と連動した感染監視システムやリアルタイム分析プラットフォームも、CRBSIの早期発見と追跡をサポートしています。標準化された中心ラインバンドル、臨床判断支援ツール、看護師主導の抜去プロトコルが、ラインケアのコンプライアンスと説明責任を推進するために導入されています。さらに、ポイント・オブ・ケア診断ツールや迅速培養システムは、タイムリーな病原体の同定と的を絞った抗生物質投与に役立ち、患者の転帰を改善しています。

CRBSI予防・管理ソリューションの需要はどこで高まり、どのような臨床環境で導入が進んでいるか？

北米は、確立された病院品質報告フレームワークと厳格なCMSおよびCDCガイドラインに支えられ、世界のCRBSI予防の取り組みをリードしています。米国は、被覆カテーテル、診断テスト、感染監視ソフトウェアの需要を引き続き牽引しています。欧州は、カテーテルケアバンドルの採用が増加し、地域全体で患者安全への取り組みが進んでいます。アジア太平洋地域は、特にインド、中国、日本などの国々で感染管理市場の力強い成長を目の当たりにしており、ICUインフラの拡大と手術件数の増加がCRBSI予防の優先順位を高めています。

主な臨床環境には、集中治療室、腫瘍科、透析センター、長期急性期病院などがあり、中心静脈アクセスが一般的で患者の脆弱性が高い環境です。さらに、在宅輸液療法や外来医療サービスにより、CRBSIリスク管理の範囲が病院の壁を越えて拡大しており、携帯型の感染予防ソリューションや患者教育ツールに対する需要が高まっています。

カテーテル関連血流感染症市場の世界的成長の原動力は？

世界のCRBSI市場は、バスキュラーアクセスデバイスの使用の増加、院内感染（HAI）に対する意識の高まり、感染管理ベンチマークを満たすための規制圧力によって牽引されています。ヘルスケアプロバイダーが予防可能な危害を減らし、臨床転帰を最適化することに注力する中、被覆カテーテル、固定システム、スタッフトレーニングプロトコルを組み合わせたバンドルソリューションへの投資が増加しています。治療費の増加、罰則、風評リスクなど、CRBSIによる経済的負担は、効果的な予防のための戦略的必要性を強化し続けています。

カテーテル材料、AIを活用した感染追跡、標的抗菌薬療法などの開発により、製品の開発と導入が加速しています。機器メーカー、感染管理チーム、医療ITベンダー間の戦略的協力により、より統合されたデータ主導型のCRBSI緩和戦略が可能になりつつあります。世界の医療システムがカテーテル関連合併症の撲滅に取り組む中、ある決定的な疑問が前進への道筋を形作っています。CRBSI予防は、標準化され、エビデンスに基づき、テクノロジーを駆使したフレームワークへと進化することができるのだろうか？

セグメント

治療タイプ（抗菌薬、抗生物質ロック療法）、感染源（コアグラーゼ陰性ブドウ球菌、黄色ブドウ球菌、腸内グラム陰性真菌、酵母、腸球菌・連鎖球菌、シュードモナス、その他の感染源）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の合計42社）

• 3M Company
• AngioDynamics Inc.
• B. Braun Melsungen AG
• Becton, Dickinson and Company
• Biomerics LLC
• Boston Scientific Corporation
• Cook Medical LLC
• ICU Medical Inc.
• IntraSpecialist Pte Ltd.
• Medcomp
• Medline Industries LP
• Medtronic plc
• Merit Medical Systems Inc.
• Navilyst Medical Inc.
• Nexus Medical LLC
• Poly Medicure Ltd.
• Pursuit Vascular（acquired by ICU Medical）
• Smiths Medical（now part of ICU Medical）
• Teleflex Incorporated
• Vygon SA

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフエコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Catheter-Related Bloodstream Infections Market to Reach US$1.9 Billion by 2030

The global market for Catheter-Related Bloodstream Infections estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Anti-Microbial Agents, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Antibiotic Lock Therapy segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$398.9 Million While China is Forecast to Grow at 7.5% CAGR

The Catheter-Related Bloodstream Infections market in the U.S. is estimated at US$398.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$380.0 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Catheter-Related Bloodstream Infections (CRBSIs) Market - Key Trends & Drivers Summarized

Why Are Catheter-Related Bloodstream Infections a Persistent Challenge in Critical Care and Hospital Infection Control?

Catheter-related bloodstream infections (CRBSIs) remain a significant cause of morbidity, mortality, and increased healthcare costs in clinical settings-particularly in intensive care units, oncology wards, and long-term care facilities. These infections arise when pathogens colonize intravascular catheters, leading to systemic bloodstream infections that complicate treatment outcomes and extend hospital stays. As central venous catheters (CVCs) are widely used for medication administration, parenteral nutrition, and hemodynamic monitoring, CRBSIs represent a serious nosocomial risk that continues to strain hospital infection control protocols.

Despite improved awareness, the global burden of CRBSIs persists due to inconsistent adherence to aseptic insertion techniques, prolonged catheter dwell times, and antimicrobial resistance. The need to minimize preventable infections is intensifying as healthcare systems prioritize quality metrics, patient safety, and cost containment-driving sustained demand for advanced prevention tools, diagnostics, and bundled care solutions targeting CRBSIs.

How Are Innovations in Catheter Materials, Antimicrobial Coatings, and Infection Surveillance Improving CRBSI Prevention?

Medical device manufacturers are advancing catheter technologies through the use of antimicrobial and antiseptic coatings (e.g., silver sulfadiazine, chlorhexidine, and minocycline-rifampin) that inhibit microbial adhesion and biofilm formation. These coated catheters are increasingly adopted in high-risk settings to reduce infection rates without compromising vascular access functionality. Improvements in catheter insertion kits, securement devices, and transparent dressings are further enhancing infection barrier protection.

Electronic health record (EHR)-linked infection surveillance systems and real-time analytics platforms are also supporting early detection and tracking of CRBSIs. Standardized central line bundles, clinical decision support tools, and nurse-driven removal protocols are being implemented to drive compliance and accountability in line care. Additionally, point-of-care diagnostic tools and rapid culture systems are aiding timely pathogen identification and targeted antibiotic administration, improving patient outcomes.

Where Is Demand for CRBSI Prevention and Management Solutions Growing and Which Clinical Environments Are Driving Adoption?

North America leads global CRBSI prevention efforts, supported by well-established hospital quality reporting frameworks and stringent CMS and CDC guidelines. The U.S. continues to drive demand for coated catheters, diagnostic tests, and infection surveillance software. Europe follows with increasing adoption of catheter care bundles and region-wide patient safety initiatives. Asia-Pacific is witnessing strong growth in infection control markets, particularly in countries like India, China, and Japan, where expanding ICU infrastructure and rising surgical volumes are heightening CRBSI prevention priorities.

Key clinical environments include intensive care units, oncology departments, dialysis centers, and long-term acute care hospitals-settings where central venous access is common and patient vulnerability is high. Additionally, home infusion therapy and ambulatory care services are expanding the scope of CRBSI risk management beyond hospital walls, driving demand for portable infection prevention solutions and patient education tools.

What Is Fueling the Global Growth of the Catheter-Related Bloodstream Infections Market?

The global CRBSIs market is being driven by the rising use of vascular access devices, growing awareness of hospital-acquired infections (HAIs), and regulatory pressure to meet infection control benchmarks. As healthcare providers focus on reducing preventable harm and optimizing clinical outcomes, investment is increasing in bundled solutions that combine coated catheters, securement systems, and staff training protocols. The financial burden of CRBSIs-through increased treatment costs, penalties, and reputational risk-continues to reinforce the strategic imperative for effective prevention.

Innovation in catheter materials, AI-enabled infection tracking, and targeted antimicrobial therapies is accelerating product development and adoption. Strategic collaborations between device manufacturers, infection control teams, and health IT vendors are enabling more integrated, data-driven CRBSI mitigation strategies. As global health systems strive to eliminate catheter-associated complications, a defining question frames the path forward: Can CRBSI prevention evolve into a standardized, evidence-based, and technology-augmented framework-while ensuring cost-effectiveness, scalability, and patient safety across varied care delivery environments?

SCOPE OF STUDY:

The report analyzes the Catheter-Related Bloodstream Infections market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Anti-Microbial Agents, Antibiotic Lock Therapy); Source of Infection (Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas, Other Sources of Infection); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• 3M Company
• AngioDynamics Inc.
• B. Braun Melsungen AG
• Becton, Dickinson and Company
• Biomerics LLC
• Boston Scientific Corporation
• Cook Medical LLC
• ICU Medical Inc.
• IntraSpecialist Pte Ltd.
• Medcomp
• Medline Industries LP
• Medtronic plc
• Merit Medical Systems Inc.
• Navilyst Medical Inc.
• Nexus Medical LLC
• Poly Medicure Ltd.
• Pursuit Vascular (acquired by ICU Medical)
• Smiths Medical (now part of ICU Medical)
• Teleflex Incorporated
• Vygon SA

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Catheter-Related Bloodstream Infections - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increased Use of Central Venous Catheters in ICUs and Oncology Elevates Risk of CRBSIs
  • Adoption of Antimicrobial and Antiseptic-Coated Catheters Reduces Infection Incidence
  • Hospital Infection Control Programs Prioritize CRBSI Prevention Through Bundled Protocols
  • Real-Time Monitoring Devices and Smart Catheter Technologies Gain Traction in High-Risk Settings
  • Surveillance Systems and EHR Integration Enable Timely CRBSI Detection and Intervention
  • ICU Workflow Automation Enhances Data Capture and Standardization in Catheter Maintenance
  • Innovation in Catheter Materials With Bacteriostatic Properties Gains Market Share
  • Global Health Initiatives Address CRBSI Prevention in Low-Resource and Field Hospital Settings
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Catheter-Related Bloodstream Infections Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Catheter-Related Bloodstream Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Catheter-Related Bloodstream Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Anti-Microbial Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Anti-Microbial Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Anti-Microbial Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Antibiotic Lock Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Antibiotic Lock Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Antibiotic Lock Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Coagulase-Negative Staphylococcus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Coagulase-Negative Staphylococcus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Coagulase-Negative Staphylococcus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for S. aureus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for S. aureus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for S. aureus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Enteric Gram-Negative Bacilli by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Enteric Gram-Negative Bacilli by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Enteric Gram-Negative Bacilli by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Yeasts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Yeasts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Yeasts by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Enterococci & Streptococci by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Enterococci & Streptococci by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Enterococci & Streptococci by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Pseudomonas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Pseudomonas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Pseudomonas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Sources of Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Sources of Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Sources of Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• JAPAN
  • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• CHINA
  • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• EUROPE
  • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Catheter-Related Bloodstream Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• FRANCE
  • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• GERMANY
  • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• INDIA
  • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Catheter-Related Bloodstream Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Catheter-Related Bloodstream Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
• AFRICA
  • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030

IV. COMPETITION